Last updated: 05/21/2019 13:50:15
A Proof of Concept Clinical Study to Investigate the Effects of an Experimental Cosmetic Moisturiser on the Barrier Function of Human Skin on the face and Forearm
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A Proof of Concept (POC) Clinical Study to Investigate the Effects of a Developmental Cosmetic Moisturising Cream on the Barrier Function of Human Skin on the Face and Forearm
Trial description: The objective of this POC clinical study is to investigate the impact of the test product (Developmental Cosmetic Moisturising Cream) on skin barrier function and skin moisturisation on the forearm and face after 4 weeks of twice daily application compared to no treatment in participants with dry sensitive skin.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Change from baseline in transepidermal water loss (TEWL) measurements on Day 29, test product treated versus (vs.) untreated sites on the forearm
Timeframe: At Baseline and Day 29
Secondary outcomes:
Change from baseline in transepidermal water loss (TEWL) measurements on Day 29, test product treated vs. untreated sites on the face
Timeframe: At Baseline and Day 29
Change from baseline in corneometry on the forearm and face, test product treated vs. untreated sites
Timeframe: At Baseline, Day 1 (30 minutes and 6 hours post study product application), Day 2, 15, and 29
Change from baseline in transepidermal water loss (TEWL) on the forearm and face, test product treated vs. untreated sites at Day 2 and 15
Timeframe: At Baseline, Day 2, and 15
Standardised area under curve (AUC1-29) of change from baseline in corneometry over treatment period
Timeframe: Up to Day 29
Standardised area under curve (AUC1-29) of change from baseline in transepidermal water loss (TEWL) over treatment period
Timeframe: Up to Day 29
Change from pre-challenge in transepidermal water loss (TEWL) measurements of D-Squame discs following 4, 8 and 12 adhesive discs removal from skin of both test product treated and untreated sites on the forearm on Day 29
Timeframe: On Day 29 (including Pre-challenge)
Change from pre-challenge in transepidermal water loss (TEWL) measurements of D-Squame discs following 3, 6 and 9 adhesive discs removal from skin of both test product treated and untreated sites on the face on Day 29
Timeframe: On Day 29 (including Pre-challenge)
Protein analysis (SquameScan) of D-Squame discs (total of 12 adhesive discs) from skin of both test product treated and untreated sites on the forearm on Day 29
Timeframe: On Day 29
Protein analysis of D-Squame discs (total of 9 adhesive discs) from skin of both test product treated and untreated sites on the face on Day 29
Timeframe: On Day 29
Change from baseline in transepidermal water loss (TEWL) measurements on Days 30, 31, 32, 33 and 34 in test product treated vs. untreated sites on the forearm and face
Timeframe: At Baseline, Day 29, 30, 31, 32, 33,and 34
Change from Day 29 in transepidermal water loss (TEWL) measurements on Days 30, 31, 32, 33 and 34 in test product treated vs. untreated sites on the forearm and face
Timeframe: At Day 29, 30, 31, 32, 33, and 34
Change from baseline in standardised Area Under Curve (AUCday 29-34) of transepidermal water loss (TEWL) over regression period (Days 30, 31, 32, 33 and 34) of forearm and face, test product treated vs. untreated sites
Timeframe: Up to Day 34
Change from Day 29 in standardised Area Under Curve (AUCday 29-34) of transepidermal water loss (TEWL) over regression period (Days 30, 31, 32, 33 and 34) of forearm and face, test product treated vs. untreated sites
Timeframe: Up to Day 34
Change from baseline in Corneometry measurements on Days 30, 31, 32, 33 and 34 in test product treated site vs. untreated site on the forearm and face
Timeframe: At Baseline, Day 30, 31, 32, 33, and 34
Change from Day 29 in corneometry measurements on Days 30, 31, 32, 33 and 34 in test product treated site vs. untreated site on the forearm and face
Timeframe: At Day 29, 30, 31, 32, 33, and 34
Standardised Area Under Curve (AUCday29-34) calculated using change from baseline in corneometry over regression period (Days 30, 31, 32, 33 and 34) on the forearm and face
Timeframe: Up to Day 34
Standardised AUC calculated using change from Day 29 in corneometry over regression period (Days 30, 31, 32, 33 and 34) on the forearm and face
Timeframe: Up to Day 34
Change from baseline in transepidermal water loss (TEWL) measurements on Day 29 of positive control treated site vs. untreated site on the forearm.
Timeframe: At Baseline and Day 29
Change from baseline in transepidermal water loss (TEWL) measurements on Days 30, 31, 32, 33 and 34 in test product treated vs. untreated sites on the forearm and face
Timeframe: At Baseline, 30, 31, 32, 33,and 34
Interventions:
Other: Test product (Moisturising cream)
Other: Positive control (Commercial market place moisturising cream)
Other: No treatment
Enrollment:
69
Observational study model:
Not applicable
Primary completion date:
2017-19-04
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Skin Care
Product
nicotinamide
Collaborators
Not applicable
Study date(s)
February 2017 to April 2017
Type
Interventional
Phase
Not applicable
Participation criteria
Sex
Female
Age
18 - 65 years
Accepts healthy volunteers
Yes
- Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- Good general and mental health with, in the opinion of the investigator or medically qualified designee no clinically significant and relevant abnormalities in medical history or upon physical examination.
- Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
- Women who are breast-feeding.
Inclusion and exclusion criteria
Inclusion criteria:
- Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- Good general and mental health with, in the opinion of the investigator or medically qualified designee no clinically significant and relevant abnormalities in medical history or upon physical examination.
- Self-reported dry, sensitive skin on the face and body.
- Agreement to comply with the procedures and requirements of the study and to attend the scheduled assessment visits.
- Trained examiner visual grading assessment score (including subject self-assessment of tightness) of overall dryness ≥ 3 with a score of at least 1 in the roughness parameter and 4 (for any individual parameter) on each of the forearms and each side of the face at the Screening visit (Visit 1) and Baseline visit (Visit 2).
- In addition, there will be no greater than 0.5 point difference between trained examiner visual grading scores of each volar forearm and each side of the face at the Screening and Baseline visits.
- Fitzpatrick skin type I-IV
Exclusion criteria:
- Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
- Women who are breast-feeding.
- Any history of significant dermatological diseases or conditions or medical conditions known to alter skin appearance or physiologic response (e.g. diabetes) which could, in the opinion of the Investigator, preclude topical application of the investigational products and/or interfere with the evaluations.
- Presence of open sores, pimples, or cysts at the application site.
- Active dermatosis (local or disseminated) that might interfere with the results of the study.
- Considered immune compromised.
- Currently using any medication which in the opinion of the investigator, may affect the evaluation of the study product, or place the subject at undue risk.
- Use of the following topical or systemic medications: immunosuppressants, antihistamines, non-hormonal anti-inflammatory drugs, and corticosteroids up to 2 weeks before screening visit.
- Intention of using any oral or topical steroids.
- Regular use of inhaled steroids (occasional use is permitted).
- Regular use of topical anti-itch medications (occasional use permitted; the product should be applied with an applicator but not to the proposed application areas.
- Use of any topical drug or medication in the proposed application areas.
- Intention of being vaccinated during the study period or has been vaccinated within 3 weeks of the screening visit.
- Currently receiving allergy injections, or received an allergy injection within 7 days prior to Visit 1, or expects to begin injections during study participation.
- Previous history of atopy, allergic reactions, irritation or intense discomfort feelings to topical-use products, cosmetics or medication.
- Known or suspected intolerance or hypersensitivity to any of the study materials (or closely related compounds) or any of their stated ingredients.
- Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 14 days of the screening visit.
- Previous participation in this study.
- Recent history (within the last 5 years) of alcohol or other substance abuse.
- Smoker (including e-cigarettes)
- Moles, tattoos, scars, hairs, etc. at the test areas if it is likely that they could affect the assessments.
- Subject has visible sunburn on the test sites.
- Use of self-tanning products on the test areas (face and arms) within 2 weeks prior to the screening visit.
- Any individual parameter score 4 on any test areas of the face or either of the forearms as assessed by a trained examiner.
- Any Subject who, in the judgment of the Investigator, should not participate in the study.
- An employee of the sponsor or the study site or members of their immediate family.
Trial location(s)
Location
GSK Investigational Site
Schenefeld, Schleswig-Holstein, Germany, 22869
Status
Study Complete
Study documents
Statistical analysis plan
Available language(s): English
Protocol
Available language(s): English
Clinical study report
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2017-19-04
Actual study completion date
2017-24-04
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website